Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

 
CAPITALIZATION
 
The following table sets forth our cash and cash equivalents and investment securities, available for sale, and capitalization as of December 31, 2006:
 
  •      on an actual basis; and
 
  •      on a pro forma as adjusted basis to reflect (a) the conversion upon the consummation of this offering of all outstanding shares of our preferred stock into 32,924,474 shares of common stock and (b) our sale of           shares of common stock in this offering and our receipt of the estimated net proceeds therefrom, based on an assumed initial public offering price of $      per share (the mid-point of the price range set forth on the cover page of this prospectus) and after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us.
 
The pro forma information below is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering to be determined at pricing. You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes appearing elsewhere in this prospectus.
 
                 
    As of December 31, 2006  
          Pro Forma as
 
    Actual     Adjusted(1)  
 
Cash and cash equivalents and investment securities, available-for-sale
    $34,413,603     $               
                 
Series A redeemable convertible preferred stock, $0.001 par value: actual — 9,322,035 shares authorized, issued and outstanding; pro forma as adjusted — no shares authorized, issued or outstanding
    $10,954,497          
Series B redeemable convertible preferred stock, $0.001 par value: actual — 14,830,509 shares authorized, issued and outstanding; pro forma as adjusted — no shares authorized, issued or outstanding
    34,942,437          
Stockholders’ equity (deficit):
               
Preferred stock, $0.001 par value: actual — no shares authorized, issued or outstanding; pro forma as adjusted — 10,000,000 shares authorized, no shares issued or outstanding
             
Series C convertible preferred stock, $0.001 par value: actual — 8,771,930 shares authorized, issued and outstanding; pro forma as adjusted — no shares authorized, issued or outstanding
    8,772          
Common stock, $0.001 par value; actual — 50,000,000 shares authorized, 4,796,084 shares issued and outstanding; pro forma as adjusted — 100,000,000 shares authorized,          shares issued and outstanding
    4,796          
Additional paid-in capital
    33,296,081          
Accumulated other comprehensive gain
    11,433          
Deficit accumulated during the development stage
    (49,168,004 )        
                 
Total stockholders’ equity
    (15,846,922 )        
                 
Total capitalization
    $30,050,012     $  
                 
 
(1) Each $1.00 increase or decrease in the assumed public offering price of $      per share (the mid-point of the price range set forth on the cover page of this prospectus) would increase or decrease, respectively, the amount of cash and cash equivalents and securities available-for-sale, additional paid-in capital and total capitalization by approximately $      million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us.


41